Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China
Infectious Medicine · 2026-06 · 5 (2) · 100258
DOI: 10.1016/j.imj.2026.100258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectious Medicine, 2026-06. Verfasst von Yamin Shu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Pharmaceutical Association, Health Commission of Hubei Province.
Abstract (Originalsprache)
Background
With population aging and the rising burden of chronic diseases, pneumococcal disease imposes increasing pressure on the healthcare system in China. This study evaluated the cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged 50 years.
Methods
A decision-tree-based static cohort Markov model was developed to estimate lifetime costs and health outcomes from a societal perspective under a hypothetical strategy of PPSV23 vaccination at age 50 with revaccination at age 65 to assess long-term protection under waning immunity; a single-dose strategy was examined in scenario analyses. The model estimated quality-adjusted life-years, life-years, incremental cost-effectiveness ratios, and cases and deaths averted. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty. Price simulations were performed across different willingness-to-pay thresholds. Safety was evaluated using the Vaccine Adverse Event Reporting System through descriptive analysis and empirical Bayesian data mining.
Results
The estimated incremental cost-effectiveness ratios for PPSV23 compared to no vaccination are $12,937.07 per quality-adjusted life-year gained and $9,622.25 per life-year gained, with the administration of PPSV23 preventing 1,115 cases and 35 deaths from a study population of 100,000 individuals. The greatest sensitivity was observed to variations in the discount rate, serotype coverage of PPSV23, vaccine efficacy of PPSV23 and cost per dose of PPSV23. No new or unexpected safety concerns for PPSV23 were identified.
Conclusions
PPSV23 is a cost-effective option for adults aged 50 years in China at higher willingness-to-pay thresholds (e.g., 2-3 × the gross domestic product per capita), with a favorable post-marketing safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- International Research Center for Medicinal Administration, Peking University, Beijing 100191, China.
- Department of Statistical Sciences, Univerisity of Toronto, Toronto M5S6E8, Canada.
- Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Förderung
- Chinese Pharmaceutical Association
- Health Commission of Hubei Province
Zitieren
APA
Shu, Y., Tan, S., Chen, Y., Ding, Y., Xu, P., & Zhang, Q. (2026). Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China. Infectious Medicine, 5(2), 100258. https://doi.org/10.1016/j.imj.2026.100258
Vancouver
Shu Y, Tan S, Chen Y, Ding Y, Xu P, Zhang Q. Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China. Infectious Medicine. 2026;5(2):100258. doi:10.1016/j.imj.2026.100258
BibTeX
@article{Shu2026,
author = {Shu, Yamin and Tan, Shuhua and Chen, Yao and Ding, Yiling and Xu, Pingping and Zhang, Qilin},
title = {Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China},
journal = {Infectious Medicine},
year = {2026},
volume = {5},
number = {2},
pages = {100258},
doi = {10.1016/j.imj.2026.100258}
}
EUVIMED